Roche $50 Billion US Investment
Analysis based on 6 articles · First reported Apr 22, 2025 · Last updated Apr 22, 2025
Roche's $50 billion investment in the United States, driven by potential tariffs from Donald Trump's administration, is expected to boost the U.S. pharmaceutical manufacturing sector and create jobs. This move, following a similar one by Novartis, signals a broader trend of pharmaceutical companies increasing their U.S. footprint to mitigate trade policy risks, potentially impacting global drug supply chains and benefiting the United States economy.
Roche, a Swiss pharmaceutical giant, announced a $50 billion investment in the United States over the next five years. This significant investment, which will expand existing facilities, build new manufacturing plants, and establish research centers, is largely a response to President Donald Trump's threats of imposing tariffs as high as 25% on pharmaceutical imports. The investment is expected to create over 12,000 new jobs in the United States, with 1,000 directly at Roche and 6,500 in construction. Roche's CEO, Thomas Schinecker, stated that these investments underscore the company's long-standing commitment to research, development, and manufacturing in the United States. This move follows a similar $23 billion investment by Swiss competitor Novartis earlier this month, indicating a trend among pharmaceutical companies to bolster their U.S. presence to avoid potential trade disruptions and tariffs.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard